Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second pivotal Phase III study of Piclidenoson

Next Previous
Trial Profile

Second pivotal Phase III study of Piclidenoson

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 24 Mar 2025 According to a Can-Fite BioPharma media release, the Company plans to submit a New Drug Application (NDA) to the U.S. FDA and Marketing Authorization Plan (MAA) to the EMA, after positive conclusion of the Phase 3 program.
  • 18 Dec 2023 According to a Can-Fite BioPharma media release, the company received a positive response from the U.S. Food and Drug Administration (FDA) on the Pediatric Study Plan for the treatment of children suffering from psoriasis with Piclidenoson. The plan has been submitted to allow enrollment of children with psoriasis to one or both of the Phase 3 studies.
  • 05 Jul 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top